Intake of copper has no effect on cognition in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial

Journal of Neural Transmission (Impact Factor: 3.05). 08/2008; 115(8):1181-1187. DOI: 10.1007/s00702-008-0080-1
Source: PubMed

ABSTRACT Disturbed copper (Cu) homeostasis may be associated with the pathological processes in Alzheimer’s disease (AD). In the present
report, we evaluated the efficacy of oral Cu supplementation in the treatment of AD in a prospective, randomized, double-blind,
placebo-controlled phase 2 clinical trial in patients with mild AD for 12months. Sixty-eight subjects were randomized. The
treatment was well-tolerated. There were however no significant differences in primary outcome measures (Alzheimer’s Disease
Assessment Scale, Cognitive subscale, Mini Mental Status Examination) between the verum [Cu-(II)-orotate-dihydrate; 8mg Cu
daily] and the placebo group. Despite a number of findings supporting the hypothesis of environmental Cu modulating AD, our
results demonstrate that oral Cu intake has neither a detrimental nor a promoting effect on the progression of AD.


Full-text (2 Sources)

Available from
Jun 1, 2014